You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Pocket Potty Program- Toilet Training for Children with Developmental Disabilities

    SBC: SANDBOX LEARNING COMPANY            Topic: 84133S1

    This Phase I project develops and evaluates a mobile application for teaching elementary and middle school aged children with intellectual and developmental disabilities toilet training skills. A team of educational experts, technology experts, and parent of a child with autism collaborate on the project to ensure the mobile application has the greatest benefit. Specific goals include: (1) develop ...

    SBIR Phase I 2012 Department of Education
  2. Speech-based biomarkers of CNS dysfunction associated with early Alzheimers disea

    SBC: KOBAK, KENNETH A            Topic: NIA

    DESCRIPTION (provided by applicant): More efficient methods to screen and monitor elderly patients in clinical practice and research are needed, but visits to clinical offices are expensive and many older patient are restricted by mobility or transportation access. The Alzheimer's Disease Cooperative Study (ADCS) is evaluating several technology platforms for remotely monitoring patient stat ...

    STTR Phase I 2012 Department of Health and Human ServicesNational Institutes of Health
  3. Novel Biomarkers for Early Detection of Aspergillosis

    SBC: SOUTHEAST TECHINVENTURES INC            Topic: NIAID

    DESCRIPTION (provided by applicant): Invasive aspergillosis (IA) caused by the fungus Aspergillus fumigatus is the most frequent fungal cause of death in immunocompromised patients. The number of patients at risk for developing IA is steadily increasing due to advances in medicine. Early and accurate diagnosis of IA is critical to patient outcome, yet is exceedingly difficult due to the lack of sp ...

    STTR Phase I 2012 Department of Health and Human ServicesNational Institutes of Health
  4. Treating EAE disease with Fc-Dimers

    SBC: LeukoSight Inc            Topic: NIAID

    DESCRIPTION (provided by applicant): We have developed a recombinant polypeptide that we have termed Fc-Dimers (Di -mers). This product has potent anti-inflammatory activity in vitro, and we propose to test this reagent in an animal model of autoimmunedisease. We have selected the murine disease, Experimental Autoimmune Encephalomyelitis (EAE), a model for human multiple sclerosis (MS). Pathol ...

    STTR Phase I 2012 Department of Health and Human ServicesNational Institutes of Health
  5. CMV Therapeutic Vaccine for the Treatment of Glioblastoma

    SBC: Annias Immunotherapeutics, Inc.            Topic: NCI

    DESCRIPTION (provided by applicant): Recently, temozolomide (TMZ), a myelosuppressive alkylating chemotherapy, has shown a benefit in patients with glioblastoma multiformes (GBM), but median survival is still less than 15 months. Moreover, these conventional chemotherapies lack specificity and result in incapacitating damage to surrounding normal brain and systemic tissues. Immunotherapy may provi ...

    STTR Phase I 2012 Department of Health and Human ServicesNational Institutes of Health
  6. A Quantitative Optical Sensor to Monitor Pre-Clinical Tumor Vascular Physiology

    SBC: Zenalux Biomedical, Inc.            Topic: NCI

    DESCRIPTION (provided by applicant): Angiogenesis and hypoxia can significantly influence the efficacy of therapy and the behavior of surviving tumor cells. This important fact is supported by a vast amount of literature on pre-clinical models and clinical studies. There is growing demand for technologies to measure tumor hypoxia and angiogenesis temporally and spatially in vivo to enable advance ...

    STTR Phase I 2012 Department of Health and Human ServicesNational Institutes of Health
  7. Novel SET Antagonists for the Treatment of Chronic Myelogenous Leukemia

    SBC: ONCOTIDE PHARMACEUTICALS, INC.            Topic: NCI

    DESCRIPTION (provided by applicant): Chronic Myelogenous Leukemia (CML) affects nearly 14,000 patients worldwide and is a disorder of the pluripotent hematopoietic stem cells with two distinct phases. The protracted myelopoliferative chronic phase is followed by a rapidly fatal blast crisis. In CML, a chromosomal translocation leads to production of the Philadelphia Chromosome (Ph1) in which the ...

    STTR Phase I 2012 Department of Health and Human ServicesNational Institutes of Health
  8. QuitAdvisorOB: A tool for delivering smoking cessation guidance to pregnant women

    SBC: HEALTH DECISION TECHNOLOGIES, LLC            Topic: NIDA

    DESCRIPTION (provided by applicant): The long-term objective of this project is to provide a smoking-cessation intervention tool for health care providers in prenatal settings. Smoking during pregnancy is a significant public health issue. The prevalence of smoking in women of child-bearing age generally ranges between 17 and 35 percent worldwide, and is heavily influenced by maternal age, ethnici ...

    STTR Phase I 2012 Department of Health and Human ServicesNational Institutes of Health
  9. Development of a Novel Class for Opioid Drugs

    SBC: ALGYNOMICS, INC.            Topic: NIDA

    DESCRIPTION (provided by applicant): The mu-opioid receptor (MOR) is the primary target for opioid analgesics. While opioids are the most frequently used and effective analgesics for the treatment of moderate to severe clinical pain, their prolonged use leads to reduced efficacy and a number of adverse side effects, including post dosing-induced hyperalgesia and analgesic tolerance. MOR induces an ...

    STTR Phase I 2012 Department of Health and Human ServicesNational Institutes of Health
  10. Significant CT Radiation Dose Reduction with Equally Sloped Tomography

    SBC: TOMOSOFT TECHNOLOGIES, LLC            Topic: NIBIB

    DESCRIPTION (provided by applicant): CT has become a routine medical tool in diagnosis of diseases and visualization of critical interventional procedures. The number of CT examinations has significantly increased over the past two decades in the US, and reached approximately 72 million in 2007 alone [5,8]. According to the 2009 report from the National Council on Radiation Protection and Measurem ...

    STTR Phase I 2012 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government